Oprozomib

Oprozomib 구조식 이미지
카스 번호:
935888-69-0
상품명:
Oprozomib
동의어(영문):
Axelopran;PR 047;CS-696;ONX-0912;OprozoMib;0prozomib;Oprozomib, >=98%;LY335979 ONX-0912;0prozoMib(ONX0912);ONX-0912(Oprozomib)
CBNumber:
CB52628218
분자식:
C25H32N4O7S
포뮬러 무게:
532.61
MOL 파일:
935888-69-0.mol

Oprozomib 속성

녹는점
147-150°C (dec.)
끓는 점
849.9±65.0 °C(Predicted)
밀도
1.290±0.06 g/cm3(Predicted)
저장 조건
-20°C Freezer
용해도
DMSO(약간 용해됨), 메탄올(약간 용해됨)
산도 계수 (pKa)
12.29±0.46(Predicted)
물리적 상태
고체
물리적 상태
단단한 모양
색상
흰색에서 황백색까지

안전

Oprozomib C화학적 특성, 용도, 생산

개요

ONX 0912 is an orally bioavailable proteasome inhibitor. It potently targets the chymotrypsin-like activity of the 20S proteasome subunits β5 and LMP7 (IC50s = 36 and 82 nM, respectively). ONX 0912 inhibits the growth of multiple myeloma cells at nanomolar concentrations while not decreasing the viability of normal peripheral blood mononuclear cells at 1 μM. It blocks the growth of xenografted human multiple myeloma cells in mice when given orally. ONX 0912 has potential applications in certain types of cancer as well as other diseases that require proteasome activity.

용도

Oprozomib is the second class of proteasome inhibitors with higher specificities and reduced toxicities, against head and neck squamous cell carcinoma.

효소 저해제

This orally active inhibitor (FW = 532.61 g/mol; CAS 935888-69-0; Solubility: 105 mg/mL DMSO, <1 mg/mL H2O), also known as ONX 0912 and O-methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)-ethyl]-Lserinamide, selectively targets the chymotrypsin-like (CT-L) activity of 20S proteasome β5 (IC50 = 36 nM) and 20S proteasome LMP7 (IC50 = 82 nM). In animal tumor model studies, ONX 0912 significantly reduced tumor progression and prolonged survival. Immununostaining of multiple myeloma tumors from ONX 0912-treated mice showed growth inhibition, apoptosis, and a decrease in associated angiogenesis. Oprozomib is distinct from carfilzomib, even though the same chemistry was employed to selectively target the proteasome. Oprozomib is under development as an oral therapy for hematologic malignancies, including multiple myeloma, and for patients with recurrent or refractory solid tumors (See also Carfilzomib).

Oprozomib 준비 용품 및 원자재

원자재

준비 용품


Oprozomib 공급 업체

글로벌( 123)공급 업체
공급자 전화 이메일 국가 제품 수 이점
Alpha Biopharmaceuticals Co., Ltd
+86-411-39042497 +8613921981412
sales@alphabiopharm.com China 886 58
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795
ivan@atkchemical.com China 32480 60
Hubei Jusheng Technology Co.,Ltd.
18871490254
linda@hubeijusheng.com CHINA 28180 58
Changzhou PBpharmaceutical R&D Co.,Ltd
0519-83990708
info@pbpharm.com CHINA 498 58
career henan chemical co
+86-0371-86658258 15093356674;
factory@coreychem.com China 29826 58
Baoji Guokang Bio-Technology Co., Ltd.
0917-3909592 13892490616
gksales1@gk-bio.com China 9339 58
Zhejiang J&C Biological Technology Co.,Limited
+1-2135480471 +1-2135480471
sales@sarms4muscle.com China 10523 58
InvivoChem
+1-708-310-1919 +1-13798911105
sales@invivochem.cn United States 6393 58
LEAP CHEM CO., LTD.
+86-852-30606658
market18@leapchem.com China 24738 58
Hangzhou MolCore BioPharmatech Co.,Ltd.
+86-057181025280; +8617767106207
sales@molcore.com China 49739 58

Copyright 2019 © ChemicalBook. All rights reserved